Breast Cancer Research and Treatment

, Volume 140, Issue 3, pp 567–575

Therapeutic effect of β-blockers in triple-negative breast cancer postmenopausal women

Authors

    • Division of Epidemiology and BiostatisticsEuropean Institute of Oncology
  • Elisabetta Munzone
    • Division of Medical SenologyEuropean Institute of Oncology
  • Nicole Rotmensz
    • Division of Epidemiology and BiostatisticsEuropean Institute of Oncology
  • Carlo Cipolla
    • Division of CardiologyEuropean Institute of Oncology
  • Vincenzo De Giorgi
    • Department of DermatologyUniversity of Florence
  • Barbara Santillo
    • Division of Epidemiology and BiostatisticsEuropean Institute of Oncology
  • Arnaldo Zanelotti
    • Division of CardiologyEuropean Institute of Oncology
  • Laura Adamoli
    • Department of MedicineEuropean Institute of Oncology
  • Marco Colleoni
    • Division of Medical SenologyEuropean Institute of Oncology
  • Giuseppe Viale
    • Department of Pathology and Laboratory MedicineEuropean Institute of Oncology
    • University of Milan
  • Aron Goldhirsch
    • Department of MedicineEuropean Institute of Oncology
  • Sara Gandini
    • Division of Epidemiology and BiostatisticsEuropean Institute of Oncology
Epidemiology

DOI: 10.1007/s10549-013-2654-3

Cite this article as:
Botteri, E., Munzone, E., Rotmensz, N. et al. Breast Cancer Res Treat (2013) 140: 567. doi:10.1007/s10549-013-2654-3

Abstract

Beta-blockers (BB) drugs have been used for decades worldwide, mainly to treat hypertension. However, in recent epidemiological studies, BBs were suggested to improve cancer prognosis. In the wake of this evidence, we evaluated the possible therapeutic effect of BBs in triple-negative breast cancer (TNBC) patients. We identified 800 postmenopausal women operated between 1997 and 2008 for early primary TNBC. The effect of BB intake on the risk of breast cancer (BC) recurrence and death was evaluated through competing risk and Cox regression survival models. At cancer diagnosis, 74 (9.3 %) women out of 800 were BBs users. Median age was 62 years in BB users and 59 years in non-users (P = 0.02). BB users and non-users were similarly distributed by all tumor characteristics. The 5-year cumulative incidence of BC-related events was 13.6 % in BB users and 27.9 % in non-users (P = 0.02). The beneficial impact of BBs remained statistically significant at multivariable analysis (HR, 0.52; 95 % CI 0.28–0.97), after the adjustment for age, tumor stage, and treatment, peritumoral vascular invasion and use of other antihypertensive drugs, antithrombotics, and statins. Adjusted HRs for metastases and for BC deaths were 0.32 (95 % CI 0.12–0.90) and 0.42 (95 % CI 0.18–0.97), respectively, in favor of BBs. Hypertension, other antihypertensive drugs, antithrombotics, and statins did not impact prognosis. In this series of postmenopausal TNBC patients, BB intake was associated with a significantly decreased risk of BC-related recurrence, metastasis, and BC death. Innovative therapeutic strategies including BBs should be urgently explored in cancer patients.

Keywords

Beta-blockersBreast cancerTriple negativePrognosis

Supplementary material

10549_2013_2654_MOESM1_ESM.pdf (8 kb)
Supplementary material (PDF 8 kb)
10549_2013_2654_MOESM2_ESM.doc (30 kb)
Supplementary material (DOC 29 kb)

Copyright information

© Springer Science+Business Media New York 2013